Introduction
============

Globally, there were 951,600 new gastric cancer (GC) cases and accounted for 723,100 deaths in 2012[@B1]. GC is a major public health burden internationally, especially in parts of the developing countries (677,100 new cases in 2012). Recently, some therapeutic advances its prognosis is often unfavourable, and despite the decrease in overall incidence[@B2]. Thus, effective and inexpensive strategies for prevention of GC are urgently needed in the developing world.

Non-steroidal anti-inflammatory drug (NSAID) are a structurally diverse group of drugs that are most widely used to treat pain, inflammation and fever over the past decades, fundamentally including aspirin, celecoxib, acetaminophen, and other NSAIDs. These drugs are inhibitors of the enzyme cyclooxygenase (COX) and thereby affect the production of prostaglandin signalling molecules (PGs). Two isoforms of COX are well-known: COX-1 for the production of PGs during basal conditions in the gastrointestinal tract and an inducible COX-2 regulated by growth factors, mitogens, and tumor promoters [@B3]. Until recently, compelling data from a large and rapidly expanding body of studies indicate that aspirin and other NSAIDs is associated with a decreased risk of colorectal, lung, and other carcinomas [@B4]-[@B6]. Nevertheless, the exact mechanism of risk reduction is still undetermined but may be related to these agents have decreased the level of prostaglandin E2 (PGE2). It is reported that PGE2 may modulate various immune responses, increase cells\' longevity via inhibition of apoptosis, and stimulate cancer cell proliferation [@B7]-[@B9]. Since 1970s, a host of prior large epidemiologic studies and meta-analyses strongly support a protective association between aspirin/NSAIDs ingestion and gastric adenocarcinomas [@B10]-[@B18]. However, several studies argue that using aspirin or other NSAIDs does not lower risk of GC [@B19]-[@B21]. More recently, many novel studies have payed close attention to this topic [@B22]-[@B29]. Therefore, it is necessary to conduct an update meta-analysis for aspirin/NSAIDs use and GC. In addition, it is still unclear that the optimal regiment for GC prevention.

In the present study, we performed an update systematic review of existing studies to explore the association between aspirin/NSAID intake and GC risk and a better benefit regiment for GC risk reduction.

Materials and Methods
=====================

Search strategy
---------------

We aimed to conduct a systematic review (according to PRISMA statement) identify association between anti-inflammatory drug exposure and risk of gastric cancer. A literature search was performed in the databases of Medline (PubMed), Web of Science, Embase, OVID, Cochrane Library and Clincialtrials.gov before August 31, 2015 for related publications, using the following key words: ("aspirin" or "NSAIDs" or "non-steroidal" or "anti-inflammatory" or "cyclooxygenase inhibitors" or "COX") combined with ("gastric cancer" or "stomach cancer" or "gastric adenocarcinoma" or "stomach adenocarcinoma" ) (for detail search terms see Supplementary Table [S1](#SM1){ref-type="supplementary-material"}).The retrieved articles were strictly examined to exclude duplicates or overlapping studies. In addition, reference lists of all retrieved articles and previous Meta-analyses were also checked for further eligible publications.

Selection criteria
------------------

Eligibility of articles were assessed independently by two reviewers (P. F. Kong and J. J. Liu). Our inclusion criteria for article were as follows: (1) exposure to any type of anti-inflammatory drugs; (2) measured the occurrence of gastric cancer; (3) randomized clinical trials (RCTs), cohort studies, or case-control studies; and (4) the odds ratios (OR) or relative risks (RR) and corresponding 95 % confidence intervals (CIs) were provided directly or calculated indirectly. In addition, reference lists of all retrieved articles and previous systematic reviews were checked for further qualified publications. For the multiple articles from the same population or data sets, only the most detailed or recent information were extracted. If necessary, authors were contacted for the detail or additional unpublished data. Animal studies, review articles, case reports, editorials, commentaries, and duplicate studies were excluded. The entire process of study selection is summarized in Figure [1](#F1){ref-type="fig"}.

Data extraction and assessment
------------------------------

Two reviewers (P. F. Kong and R. Y. Wu) extracted the data independently and any disagreement was resolved by discussion. Briefly, the following information and potential confounders were extracted: first author, publication year, country, study design, population characteristics (i.e., number, age, and follow-up duration), medication type, frequency of use, information source for exposure measurement, and total number of persons or person years in each comparison group. Additionally, we evaluated the quality of the included studies using the Newcastle-Ottawa scale [@B30].

Statistical analysis
--------------------

Our meta-analysis was conducted to assess the efficacy of pre-diagnosis aspirin usage on incidence of GC. For observational study, we used the PRISMA guidelines for meta-analysis on data extraction, analysis, and reporting. Heterogeneity between individual studies was quantified by χ^2^ test and*I^2^* test, respectively. p\<0.05 and/or *I^2^*\>50% suggests significant heterogeneity [@B30]. Summary RRs (HRs) and 95% CI were calculated using a random-effects model for *I^2^*\>50%, and a fixed-effects model was applied when the heterogeneity was not significant. The Galbraith plots was used to visualize the impact of individual studies on the overall homogeneity test statistic [@B31]. Subgroup analyses were further conducted according to study designs (case-control, cohort or RCT), sample sources (population-based or hospital-based), geographical region (North America, Europe, and Asia), sites of cancer (cardia or non-cardia), exposure type (aspirin, celecoxib, acetaminophen, COX-2 inhibitors, and other NSAIDs), use at reference date (former and current), study quality (high and low), publication year (≤2000 and \>2000), sample size (≤1000 and \>1000), frequency, duration, dose effects (\<200mg, 200 to 750 mg, \>750mg), and adjustments for covariates, so as to investigate the deprive of heterogeneity. Sensitivity and subgroup analyses were used to dissect the heterogeneity. As described previously, to evaluate the publication bias risk, funnel plots were evaluated. Two-sided p values were calculated, with a p value \<0.05 considered significant for all tests. All analyses were performed using the Stata software (V.19.0; Stata Corp, College Station, Texas, USA) [@B32].

Results
=======

Search results, study characteristics and quality Assessment
------------------------------------------------------------

Our search strategy identified 18530 articles for eligibility, of which 257 were potentially relevant upon initial inspection of study topics. Forty-seven studies, comprising 2,345,540 patients and over 13,500 events reported the association between anti-inflammatory drug use and the risk of GC, met all of the selection criteria and were included in our meta-analysis (Figure [1](#F1){ref-type="fig"}) [@B10]-[@B15], [@B19], [@B21]-[@B29], [@B33]-[@B63]. Of these enrolled articles, nine were RCT studies [@B12], [@B23], [@B27], [@B29], [@B38], [@B44], [@B48], [@B52], [@B61], fifteen were cohort studies [@B15], [@B24], [@B26], [@B28], [@B33]-[@B37], [@B45], [@B46], [@B58]-[@B60], [@B62], and the remaining twenty-three were case-control studies [@B10], [@B11], [@B13], [@B14], [@B21], [@B22], [@B24], [@B25], [@B39]-[@B43], [@B47], [@B49]-[@B51], [@B53], [@B54], [@B56], [@B57], [@B63]. In our study, there were conducted, respectively, seventeen in North America [@B13]-[@B15], [@B21], [@B28], [@B35]-[@B37], [@B39], [@B43], [@B44], [@B47], [@B48], [@B53], [@B54], [@B57], [@B58], seventeen in Europe [@B11], [@B12], [@B27], [@B33], [@B34], [@B38], [@B40]-[@B42], [@B45], [@B46], [@B49], [@B50], [@B59], [@B60], [@B62], [@B63], eleven in Asia [@B22]-[@B26], [@B29], [@B51], [@B52], [@B61], and two in Australia [@B10], [@B56]. Additionally, the detail characteristics of the included studies are presented in Table [1](#T1){ref-type="table"} and Supplementary Table [S2](#SM1){ref-type="supplementary-material"}.

As shown in Supplementary Table [S3](#SM1){ref-type="supplementary-material"} and Supplementary Table [S4](#SM1){ref-type="supplementary-material"}, the methodological quality scores of 38 included observational studies ranged from 6 to 9, with an average of 7.95. The average scores were 7.96 for case-control studies and 7.93 for cohort studies, respectively. In addition, RCTs quality scores were also evaluated in Supplementary Table [S5](#SM1){ref-type="supplementary-material"}. Altogether, we demonstrated mostly enrolled studies with a high quality in our study.

Anti-inflammatory drug intake and gastric cancer risk
-----------------------------------------------------

A pooled analysis was conducted on all 47 studies. The multivariable-adjusted RRs for each study and the combined RR for anti-inflammatory drug intake and the risk of GC are presented in Figure [2](#F2){ref-type="fig"}. Among all studies, 42 showed an inverse association between the anti-inflammatory drug and GC risk, 14 of which were statistically significant. Overall, the pooled analysis represented a summary RR of 0.78 (95% CI 0.71 to 0.85) with significant heterogeneity (*I*^2^=78.7%, p\<0.0001).

In addition, the RRs were 0.84 (95% CI 0.65 to 1.10) for RCT studies, 0.81 (95% CI 0.67-0.98) for cohort studies, and 0.84 (95% CI 0.70 to 1.00) for case-control studies, respectively. In the six studies focus on GC-specific risk, there were in a relative low quality when using the Newcastle-Ottawa scale system to evaluate. [@B25], [@B29], [@B48], [@B51], [@B59], [@B61] After excluding the study with relative low quality, the heterogeneity extremely decreased across all studies (*I*^2^=39.0%, p=0.007) and the adjusted RRs were 0.74 (95% CI 0.71 to 0.77) (Figure [2](#F2){ref-type="fig"}). Accordingly, anti-inflammatory drug intake can significantly reduce the risk of GC.

Frequency and duration of anti-inflammatory drug use
----------------------------------------------------

As shown in Table [2](#T2){ref-type="table"}, the frequency of aspirin, COX-2 inhibitors and other NSAIDs use was divided into 4, 2, and 3 subgroups, respectively. We found an apparent trend with increasing frequency of drug use and GC risk reduction. On the one hand, in aspirin group, RR= 0.91 95% CI 0.77-1.08, for 1 to 15 times/month users; RR = 0.79, 95% CI 0.64-0.98, for 16 to 29 times/month users; RR = 0.74, 95% CI 0.59-0.92, for \>30 times/month users. On the other hand, in other NSAIDs group, RR= 0.97 95% CI 0.77-1.21, for 1 to 15 times/month users; RR = 0.98, 95% CI 0.79-1.23, for 16 to 29 times/month users; RR = 0.72, 95% CI 0.59-0.88, for \>30 times/month users. In addition, we also divided the duration time of different anti-inflammatory drugs into 4 (aspirin subgroup: ≤1 years, 2 to 5 years, 6 to 9 years, and \>10 years), 2 (COX-2 subgroup: ≤1 years and 2 to 5 years), and 3 (other NSAIDs subgroup: ≤1 years, 2 to 5 years, and 6 to 9 years), respectively. Notably, we observed an unexpected trend of decreasing risk of GC associated with decreasing duration of anti-inflammatory drugs use. For instance, in aspirin group, RR= 0.69 95% CI 0.48-0.99, for ≤1 years users; RR = 0.74, 95% CI 0.63-0.87, for 2 to 5 years\' users; RR = 0.81, 95% CI 0.59-1.13, for 6 to 9 years\' users; RR = 0.86, 95% CI 0.48-1.55, for \>10 years users. Furthermore, in COX-2 inhibitors users, compare with daily intake subgroup (RR = 0.48, 95% CI 0.30-0.78), the summary RR for twice daily intake subgroup (RR = 0.30, 95% CI 0.09-1.07) was lower. In our study, a linear positive correlation trend was found between duration of aspirin use and GC risk, though the result was not statistically significant (P for linear trend = 0.210; Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}). As a consequence, we unravel a tendency towards stronger risk reduction for more frequent and short term aspirin usage.

Dose-response effect
--------------------

Twelve studies that reported the RR and its 95% CI for the exact dose were included in our dose-response meta-analysis, six for aspirin [@B19], [@B21], [@B38], [@B52], [@B53], [@B62], five for COX-2 inhibitors [@B25], [@B27], [@B50], [@B51], [@B59], and one for other NSAIDs [@B28]. The summary RR for \< 200 mg/day of aspirin was 0.63 (95% CI, 0.49-0.81) with a heterogeneity (P =0.141, *I* ^2^=42.1%). However, for users of more than 200 mg/day, there were no monotonically decreasing trend, and on the contrary, a monotonically increasing trend was observed (RR =0.76, 95% CI 0.59-0.98, for 200 to 750 mg/day; RR = 0.94, 95%CI 0.58-1.54, for \>750 mg/day). Additionally, the summary RR for 200 mg/day of COX-2 inhibitors was 0.50 (95% CI, 0.30-0.84) without heterogeneity (P =0.989, *I* ^2^= 0.0%). The rest results present in Supplementary Table [S6](#SM1){ref-type="supplementary-material"} and Figure [3](#F3){ref-type="fig"}.

Subgroup analysis
-----------------

### 1). Study design

Subgroup analysis by study design was conducted. Significant inverse associations were observed in cohort studies (RR, 0.81; 95% CI, 0.67-0.98) and case-control studies (RR, 0.84; 95% CI, 0.70-1.00). In addition, pooled analysis of RCTs showed a borderline significant decrease in GC to be associated with anti-inflammatory drug intake (RR, 0.84 95% CI, 0.65-1.10). (Table [3](#T3){ref-type="table"}).

### 2). Geographic area

Studies were stratified by geographic area, The RRs were 0.71 (95% CI, 0.64-0.79) for studies conducted in North America, 0.83 (95% CI, 0.72-0.96) for studies in Europe. These results indicate a significant inverse association between anti-inflammatory intake and GC risk (Supplementary Table [S7](#SM1){ref-type="supplementary-material"}).

### 3). Site of cancer

The possible association between the use of NSAIDs and site of GC was reported by twenty-three studies, thirteen in cardia [@B11]-[@B15], [@B26], [@B40], [@B41], [@B52], [@B54]-[@B57], and ten in non-cardia [@B11]-[@B15], [@B40], [@B52], [@B55]-[@B57]. In this subgroup analysis, cardia and non-cardia group both were existed heterogeneity, and all of the pooled analyses yielded statistically significant RRs. The protective effect of NSAIDs for non-cardia GC, with a pooled RR of 0.63 (95% CI: 0.54-0.73), was greater than that for cardia GC, with a summary RR of 0.80 (95% CI: 0.73-0.87) (Supplementary Table [S7](#SM1){ref-type="supplementary-material"}).

### 4). Anti-inflammatory drug type

Among subgroup analyses stratified by anti-inflammatory drug types, studies on aspirin (RR, 0.80; 95% CI, 0.73-0.87)[@B10]-[@B15], [@B19], [@B21], [@B23], [@B24], [@B35], [@B36], [@B38], [@B40], [@B47]-[@B49], [@B52]-[@B57], [@B61]-[@B63], studies on celecoxib (RR, 0.49; 95% CI, 0.30-0.81)[@B25], [@B27], [@B50], studies on acetaminophen (RR, 0.95; 95% CI, 0.83-1.10)[@B13], [@B54], studies on COX-2 inhibitors (RR, 0.45; 95% CI, 0.29-0.70)[@B25], [@B27], [@B50], [@B51], [@B59], and studies on other NSAIDs (RR, 0.81; 95% CI, 0.75-0.89)[@B12]-[@B15], [@B22], [@B26], [@B28], [@B29], [@B33], [@B34], [@B37], [@B39]-[@B46], [@B48], [@B49], [@B52], [@B54]-[@B58], [@B60]. Except the acetaminophen group, all of other groups showed statistically significant RRs, the outcomes indicated anti-inflammatory drug intake can reduce the risk of GC (Table [3](#T3){ref-type="table"}).

Sensitivity analyses and evaluation of heterogeneity
----------------------------------------------------

Sensitivity analyses were performed to explore possible causes of heterogeneity and the effect of various exclusion criteria on the overall result were examined. Twenty-two studies that were not adjusted for smoking, alcohol consumption, and BMI (body mass index) were omitted [@B10], [@B11], [@B19], [@B22], [@B28], [@B33], [@B34], [@B37], [@B39], [@B41], [@B44]-[@B46], [@B49], [@B52], [@B53], [@B56], [@B58]-[@B60], [@B62], [@B63]. The remaining studies produced an RR of 0.74 (95% CI, 0.70-0.79), with substantial evidence of decreasing heterogeneity (P=0.043, *I^2^*= 37%). Restricting analysis to the eight studies that were adjusted for race produced similar results (RR: 0.74, 95% CI: 0.66-0.84) [@B12], [@B13], [@B35], [@B38], [@B39], [@B43], [@B52], [@B55], but heterogeneity was still detectable (P=0.014, *I^2^*= 60.1%). Further exclusion of any single study did not change the overall outcomes, which ranged from 0.78 (95% CI: 0.71-0.86) to 0.79 (95% CI: 0.72-0.87).

Meta-regression analysis demonstrated that geographic area (P=0.10), study quality (P\<0.001), and publication year of study (P=0.09) were significant sources of heterogeneity, but the outcomes indicate that study design, drug type, and study size were not the main origin of heterogeneity. Geographic area alone explained 10.12% of the τ^2^ in the meta-regression analyses, study quality explained 61.75% of the τ^2^ and publication year explained 5.44% (Supplementary Table [S8](#SM1){ref-type="supplementary-material"}).

Publication bias
----------------

The funnel plot did not show any notable asymmetry (Supplementary Figure [S2](#SM1){ref-type="supplementary-material"}). No publication bias was detected using the Begg\'s test (P = 0.551) and Egger\'s test (P = 0.070).

Discussion
==========

In this meta-analysis, data were available for more than 2.3 million individuals and more than 13,000 GC events. Our study has found several unexpected findings with important clinical implications.

First, this work provides first convincing evidence that probably short or middle-term (≤5 years), high-frequency (\>30 times per month) and low dose (\<200 mg per day) anti-inflammatory drug use is associated with a statistically significant reduction in the risk of GC. For most of the 20th century, anti-inflammatory drug commonly is a mainstay of the treatment of inflammatory and of acute pain such as stomach pain [@B64]. Currently, many studies identified that aspirin and other NSAIDs have played important roles in cancer prevention [@B65]-[@B67]. However, until recently, there has been no reliable data to unravel the exact dose and treatment regimen for optimal benefit for cancer prevention, especially in GC. In the present study, we unequivocally showed that short or middle-term (≤5 years), high-frequency (\>30 times per month) and low dose (\<200 mg per day) anti-inflammatory drug intake could be a better regimen, which was related to significantly decreased risk of GC. Commonly, it is difficult to evaluate with precision the consumption of NSAIDs. One clinical trial has shown that a daily intake of aspirin about 6.8 years (75mg) present some obvious reductions in the incidence of GC [@B38]. Another study indicates that less than one year and one or more tablets per day were also effective [@B57]. There was, however, one study argues that daily intake of aspirin about 5 years (500mg) that did not offer any protection [@B53]. In one previous meta-analysis, Ye et al concluded that long-term (\>4 years) and low-frequency (1 to 4.5 times per week) aspirin use is associated with a significant reduction in the incidence of GC [@B18]. Surprisingly, in our study, we observed an unexpected trend of decreasing risk of GC associated with decreasing duration of anti-inflammatory drugs use in aspirin and COX-2 inhibitor subgroups and the short or middle term treatment (≤5 years) had significance GC risk reduction (Table [3](#T3){ref-type="table"}). Further, as shown in Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}, years of aspirin intake was positively associated with RR in a linear regression model, but the outcome without statistically significance (F=1.69, P=0.210). We have to point out that only three studies were included in the old regression model [@B18], which is short for statistic power. However, all available data (twenty-one studies) were enrolled in our novel model. Thus, our results more reliable than the old one. In addition, another interesting finding was that high-frequency (\>30 times per month) and low dose (\<200 mg per day) anti-inflammatory drug intake likely an optimal benefit regiment for GC prevention. Similarly, it is commonly reported in many colorectal cancer studies [@B68]. A potential explain for this phenomenon might be relative low dose NSAIDs exposure avoid of many side effects such as peptic ulcers [@B69], [@B70].

Second, our data also suggest that COX-2 inhibitors use is a more effective approach to reduce GC risk, which may have an important clinical usage for the treatment of GC and certain diseases. Above all, we clearly showed that COX-2 inhibitors intake with an encouraging significance 55% reduction in the risk of GC compare with 22% in total anti-inflammatory drug. Next, in other subgroup analysis, the pooled RR of three celecoxib studies involved also supported a result (RR: 0.49, 95% CI: 0.30-0.81), similar to COX-2 inhibitor intake does. Further, in the frequency and duration analysis, we found

that short-term (≤1 years) daily COX-2 inhibitors intake is likely a better treatment than others for GC prevention. It has been reported that both mRNA expression and levels of COX-2 protein are elevated in GC tissue [@B71]. In last ten years, many animal and clinical studies have disclosed the chemopreventive effect of COX-2 inhibitors; and in particular, a few studies have strongly stated that COX-2 inhibitor prevents the development of GC [@B72]. In addition, another reason for COX-2 inhibitor intake in GC prevention is that COX-2 inhibitor has less side effects than the other NSAIDs. For instance, in COX-2 inhibitor user, the most serious adverse reaction is related to increase risk of serious cardiovascular harm [@B73]. Interestingly, it is reported that cardiovascular events elevated only when the dose over 400 mg per day [@B74]. However, in our meta-analysis, the recommended of COX-2 inhibitor intake is low dose (\<200 mg per day), which can avoid most of cardiovascular risk for the users. Additionally, selective COX-2 inhibitors can disturb renal physiology but the impacts are relatively weak and not clinically important. Accordingly, individuals are likely benefit a lot in COX-2 inhibitor intake for decrease GC risk and large-scale randomized clinical trial is further needed.

Third, the largest synthesis so far to our knowledge in the present study highlight that intake of NSAIDs intensely reduce the risk of GC. The protective rate can reach 22% after excluding the publication biases and using the adjusted dataset, but with a large between-study heterogeneity (P\<0.0001, *I^2^*= 78.7%). Indeed, after we kicked out six studies with relative low quality [@B25], [@B29], [@B38], [@B48], [@B51], [@B59], [@B61], the heterogeneity dramatically decline to 39.0% (P=0.007, *I^2^*= 39.0%) and the reduction of GC risk still significant (RR, 0.74; 95% CI, 0.71-0.77.). Hence, the main source of heterogeneity may in view of the fact that the relative low quality studies enrolled in the meta-analysis. Previously, several meta-analyses have found aspirin or NSAIDs use inversely associated with GC risk [@B16]-[@B18], [@B20], but we still have a problem that all those studies were short of statistic power and recently data. For example, the largest scale study were generally enrolled twenty-one qualified studies range from1968 to 2003 and the summary RR was also with a high heterogeneity (*I^2^*= 59.8%). In our study, we searched a multitude of online dataset and eventually forty-seven studies were included in our analysis, among of which nineteen new studies were never covered in the previous meta-analyses [@B19], [@B22]-[@B29], [@B38], [@B39], [@B44], [@B49]-[@B51], [@B53], [@B56], [@B58]-[@B60]. Nevertheless, since the deficiency of randomized clinical trials, the strength of this study was impaired for drawbacks associated with an army of observational investigations.

Conclusions and Implications
============================

In conclusion, unlike early studies, this meta-analysis is a more comprehensive and better designed study which conducted in both RCTs and observational studies and deeply discuss the most optimal regiment of anti-inflammatory drug exposure for GC risk reduction. It demonstrates clearly that short or middle-term (≤5 years), high-frequency (\>30 times per month) and low dose (\<200 mg per day) anti-inflammatory drug use is associated with a statistically significant reduction in the risk of GC. In addition, our data also strongly suggest that COX-2 inhibitors use is a more effective approach to reduce GC risk. However, because of potential bias and confounding factors, these results should be treated with caution. As a consequence, more and better-designed high relevant large clinical trials is an urgent need in the future.
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![Forest plot of anti-inflammatory drug intake and risk of gastric cancer (ever use vs, nonuse). (A) Overall and (B) adjust for study quality. The pooled relative risk was achieved using random-effects model (*I^2^*\>50%) and fix-effects model (*I^2^*≤50%). Grey square represents relative risk in each study, with square size reflecting the study-specific weight and the 95% CI represented by horizontal bars. Squares or diamonds to the left of the solid vertical line indicate benefit with anti-inflammatory drug intake.](jcav07p2247g002){#F2}
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###### 

Characteristics of included studies.

  Author/Year                  Study design   Country          Number of events   Total subjects
  ---------------------------- -------------- ---------------- ------------------ ----------------
  Gillies\[10\]/1968           HCC            Australia        6                  50
  Isomaki\[33\]/1978           Cohort         Finland          285                46101
  Gridley\[34\]/1993           Cohort         Sweden           101                11683
  Thun\[35\]/1993              Cohort         America          308                1080089
  Schreinemachers\[36\]/1994   Cohort         America          39                 12668
  Cibere\[37\]/1997            Cohort         Canada           10                 862
  TPT\[38\]**/**1998           RCT            United Kingdom   1                  5094
  Farrow\[14\]/1998            PCC            America          612                1299
  Amjad\[39\]/1998             HCC            America          16                 40
  Zaridze\[40\]/1999           HCC            Russia           448                1058
  Suleiman\[41\]/2000          PCC            United Kingdom   56                 112
  Langman\[42\]/2000           PCC            United Kingdom   188                2018
  Coogan\[43\]/2000            HCC            America          250                6083
  Akre\[11\]/2001              PCC            Sweden           397                1327
  Fischbach\[44\]/2001         RCT            America          1                  284
  Sorensen\[45\]/2003          Cohort         Denmark          276.56^\*^         344114
  S Friis\[46\]/2003           Cohort         Denmark          68                 29470
  Nomura\[47\]/2003            PCC            America          299                745
  Ratnasinghe\[15\]/2004       Cohort         America          48                 22834
  Gammon\[21\]/2004            PCC            America          350                1042
  Cook NR\[48\]/2005           RCT            America          20                 39876
  Lindblad\[49\]/2005          PCC            United Kingdom   2348               22348
  Martin W\[50\]/2005          HCC            United Kingdom   25                 616
  HB Yang\[51\]/2006           HCC            China            113                250
  Wai K\[52\]/2006             RCT            China            24                 213
  Fortuny\[53\]/2007           PCC            America          1488               8916
  Flossmann\[12\]/2007         RCT            United Kingdom   112                13664
  Duan L\[54\]/2008            PCC            America          714                2074
  Sadeghi\[56\]/2008           PCC            Australia        425                2006
  Figueroa\[57\]/2009          PCC            America          367                1062
  Cathrine\[13\]/2009          PCC            America          109                316
  Abnet CC\[28\]/2009          Cohort         America          360                311115
  Epplein M\[58\]/2009         Cohort         America          643                169292
  Wu\[26\]/2009                Cohort         China            172                52161
  Manas\[59\]/2009             Cohort         Spain            23                 302
  Steevens\[60\]/2010          Cohort         Netherland       655                120852
  Yanaoka\[61\]/2010           RCT            Japan            6                  47
  Gonzalez\[62\]/2010          Cohort         Spain            21                 478
  Bertuccio\[63\]/2010         HCC            Italy            229                872
  Rothwell\[27\]/2011          RCT            United Kingdom   71                 25570
  Lee J\[25\]/2012             HCC            Korea            983                1966
  Wong\[29\]/2012              RCT            China            9                  1024
  Sheu\[23\]/2012              RCT            China            3                  140
  Yanmin Wu\[22\]/2013         HCC            China            501                1024
  Gong\[24\]/2014              HCC            Korea            327                654
  Ajdarkosh\[22\]/2015         HCC            Iran             7                  688
  Sungmo Jung\[24\]/2015       Cohort         Korea            19                 1041

Abbreviations: HCC: hospital-based case-control, PCC: population-based case-control, RCT: Randomized, Placebo-Controlled Trial. \* The expected number of events.

###### 

Frequency and duration on anti-inflammatory drug intake and gastric cancer risk.

  Exposure type      Frequency of use   Duration of time                                                         
  ------------------ ------------------ ------------------ ----------------- ------- ----- --- ----------------- ----------
  Aspirin            Occasionally       4                  0.96(0.80,1.17)   0.714   ≤1    3   0.69(0.48,0.99)   0.047
                     1-15               6                  0.91(0.77,1.08)   0.273   2-5   7   0.74(0.63,0.87)   0.028
                     16-29              6                  0.79(0.64,0.98)   0.031   6-9   9   0.81(0.59.1.13)   0.211
                     30+                8                  0.74(0.59,0.92)   0.007   10+   2   0.86(0.48,1.55)   0.621
  COX-2 inhibitors   30 (Daily)         4                  0.46(0.29,0.72)   0.001   ≤1    3   0.48(0.30,0.78)   0.003
                     60 (Twice daily)   1                  0.42(0.08,2.13)   0.293   2-5   2   0.30(0.09,1.07)   0.064
  Other NSAIDs       1-15               7                  0.97(0.77,1.21)   0.759   ≤1    6   0.76(0.66,0.88)   \<0.0001
                     16-29              5                  0.98(0.79,1.23)   0.880   2-5   9   0.77(0.70,0.84)   \<0.0001
                     30+                7                  0.72(0.59,0.88)   0.002   6-9   6   0.75(0.65,0.87)   \<0.0001

Abbreviations: RR, relative risk, COX-2: cyclooxygenase-2, NSAIDs: nonsteroidal anti-inflammatory drugs.

###### 

Subgroup analyses of anti-inflammatory drug intake and gastric cancer risk.

                                                 Heterogeneity test              
  ----------------------- ---- ----------------- -------------------- ---------- -------
  Total                   47   0.78(0.71,0.85)   216.43               \<0.0001   78.70
  Design                                                                         
  RCT                     9    0.84(0.65,1.10)   4.46                 0.814      0.00
  Cohort                  15   0.81(0.67,0.98)   10.41                0.732      0.00
  Case-control            23   0.84(0.70,1.00)   198.25               \<0.0001   88.90
  PCC                     12   0.81(0.64,1.12)   277.73               \<0.0001   96.00
  HCC                     11   0.88(0.69,0.85)   51.00                \<0.0001   80.40
  Exposure type                                                                  
  Aspirin                 26   0.80(0.73,0.87)   61.83                \<0.0001   59.60
  Celecoxib               3    0.49(0.30,0.81)   0.04                 0.979      0.00
  Acetaminophen           2    0.95(0.83,1.10)   0.13                 0.715      0.00
  COX-2 inhibitors        5    0.45(0.29,0.70)   0.81                 0.937      0.00
  Other NSAIDs            28   0.81(0.75,0.89)   65.60                \<0.0001   58.80
  Use at reference date                                                          
  Former                  5    0.88(0.70,1.11)   8.86                 0.065      54.80
  Current                 5    0.69(0.49,0.99)   29.02                \<0.0001   86.20

Abbreviations: RR, relative risk, RCT: Randomized, Placebo-Controlled Trial, HCC: hospital-based case-control, PCC: population-based case-control, COX-2: cyclooxygenase-2, NSAIDs: nonsteroidal anti-inflammatory drugs.
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